Ultime notizie per Imunon (NASDAQ:IMNN) Azioni

Imunon

Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the body's immune system. It is a fully integrated, clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases.

Imunon Inc

RBC Capital analyst Gregory Renza maintains Pacira BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) with a Sector Perform and raises the price target from $15 to $16.

News

Price Target

Analyst Ratings

PCRX

RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $16

Investors with a lot of money to spend have taken a bearish stance on Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with SAVA, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for Cassava Sciences.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the options we uncovered, 7 are puts, for a total amount of $321,665, and there was 1 call, for a total amount of $38,840.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $50.0 for Cassava Sciences, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Cassava Sciences's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Cassava Sciences's substantial trades, within a strike price spectrum from $10.0 to $50.0 over the preceding 30 days.
<h3>Cassava Sciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731000684_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$8.5</td>
<td>$7.95</td>
<td>$8.5</td>
<td>$23.00</td>
<td>$85.0K</td>
<td>3</td>
<td align="right">125</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$8.15</td>
<td>$7.7</td>
<td>$8.15</td>
<td>$15.00</td>
<td>$72.5K</td>
<td>2.3K</td>
<td align="right">109</td>
</tr>
<tr>
<td>SAVA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$4.3</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$30.00</td>
<td>$38.8K</td>
<td>202</td>
<td align="right">393</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$35.2</td>
<td>$33.9</td>
<td>$34.6</td>
<td>$50.00</td>
<td>$34.6K</td>
<td>66</td>
<td align="right">10</td>
</tr>
<tr>
<td>SAVA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$34.8</td>
<td>$34.25</td>
<td>$34.4</td>
<td>$50.00</td>
<td>$34.4K</td>
<td>66</td>
<td align="right">40</td>
</tr>
</tbody>
</table>

<h3>About Cassava Sciences</h3>
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
After a thorough review of the options trading surrounding Cassava Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Cassava Sciences's Current Market Status</h3>
<ul>
<li>With a volume of 657,696, the price of SAVA is down -0.58% at $26.41. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 0 days.</li>
</ul>
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Cassava Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

SAVA

Looking At Cassava Sciences's Recent Unusual Options Activity

Whales with a lot of money to spend have taken a noticeably bearish stance on Block.
Looking at options history for Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) we detected 19 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 8 are puts, for a total amount of $259,286 and 11, calls, for a total amount of $458,549.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $47.5 to $110.0 for Block over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Block options trades today is 2342.05 with a total volume of 4,780.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Block's big money trades within a strike price range of $47.5 to $110.0 over the last 30 days.
<h3>Block 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731000679_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$7.9</td>
<td>$7.5</td>
<td>$7.8</td>
<td>$77.50</td>
<td>$78.0K</td>
<td>68</td>
<td align="right">101</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.2</td>
<td>$29.65</td>
<td>$29.85</td>
<td>$47.50</td>
<td>$74.6K</td>
<td>111</td>
<td align="right">25</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$70.00</td>
<td>$56.0K</td>
<td>3.2K</td>
<td align="right">280</td>
</tr>
<tr>
<td>SQ</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.6</td>
<td>$6.55</td>
<td>$6.6</td>
<td>$77.50</td>
<td>$46.2K</td>
<td>808</td>
<td align="right">152</td>
</tr>
<tr>
<td>SQ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$2.73</td>
<td>$2.65</td>
<td>$2.73</td>
<td>$85.00</td>
<td>$40.4K</td>
<td>6.9K</td>
<td align="right">220</td>
</tr>
</tbody>
</table>

<h3>About Block</h3>
Founded in 2009, Block provides payment services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. In 2023, Square's payment volume was a little over $200 million.
<h3>Current Position of Block</h3>
<ul>
<li>Trading volume stands at 5,127,017, with SQ's price down by -0.73%, positioned at $77.07.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>What The Experts Say On Block</h3>
In the last month, 1 experts released ratings on this stock with an average target price of $88.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has revised its rating downward to Outperform, adjusting the price target to $88. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Block with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Behind the Scenes of Block's Latest Options Trends

JP Morgan analyst Pablo Zuanic maintains Bowhead Specialty Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOW#NYSE">BOW</a>) with a Neutral and raises the price target from $26 to $30.

JP Morgan Maintains Neutral on Bowhead Specialty Holding, Raises Price Target to $30

United Parks &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRKS#NYSE">PRKS</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41801451/united-parks-resorts-inc-reports-third-quarter-and-first-nine-months-2024-results" rel="noreferrer noopener">third-quarter 2024</a> revenue of $545.901 million, a slight decline of 0.4% year-over-year, missing the consensus estimate of $550.473 million.
Third quarter EPS was $2.08 (+8.3% year over year), below the analyst consensus of $2.22.
Attendance reached 7 million guests. That&#8217;s down by about 100,000 or 1.4% compared to Q3 2023. The attendance decline was mainly due to Hurricanes Debby and Helene, during peak periods.
Total revenue per capita rose 1.0% to $77.66 from Q3 2023. Admission per capita increased 0.5% to $42.24, while in-park spending per capita grew 1.6% to a record $35.42.
&#8220;The combined impact of the calendar shift and the meaningfully worse weather was approximately 320,000 guests, adjusting for these impacts, attendance would have increased approximately 3% compared to the prior year quarter, as we continue to see strong demand for our parks during normalized operating conditions and we are growing total revenue per capita,&#8221; United Parks CEO Marc Swanson said.
The company delivered record in-park per capita spending during the quarter, Swanson added, citing growth for 17 of the last 18 quarters of growth
Adjusted EBITDA was $258.4 million for the quarter, a decline of 3% YoY, and the margin contracted 126 bps to 47.3%.
In Q3, the company repurchased 4.1 million shares for $211.7 million. Some $74.9 million remains in the program as of Sept. 30. An additional 0.8 million shares were repurchased for $37.7 million by November 6.
The operating cash flow for the third quarter was $122.998 million, down from $163.556 million a year ago. Free cash flow stood at $67.605 million.
Looking ahead to 2025, the company reports strong forward demand, with ticket sales, group bookings, and Discovery Cove bookings showing double-digit growth over the last year. The recently launched premium pass program, featuring enhanced benefits, has driven sales up over 10% since its debut. Year-to-date results continue to highlight the resilience of the business model and the rising demand for the parks&#8217; unique offerings.
Total liquidity stood at $759 million with a net leverage ratio of 2.98x as of Sept. 30. In the quarter, the company expanded its credit facility from $390 million to $700 million, reducing costs by 50 basis points.
Price Action: PRKS shares are trading higher by 2.08% to $58.3 at last check Thursday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>

Earnings

PRKS

United Parks Q3 Revenue Falls Short Due To Hurricane Impact, But Future Demand And Sales Show Resilience

<a href="https://www.benzinga.com/personal-finance/24/11/41757209/if-you-do-this-prepare-to-spend-thousands-on-non-necessities-says-suze-orman-her-solution-learn-">Suze Orman</a>, a trusted personal finance expert worldwide, emphasizes that individuals must be vigilant about their benefit selections during the annual open enrollment period.&nbsp;
With health plan premiums expected to increase, Orman advises closely reviewing coverage options. High-deductible health plans (HDHPs), which come with lower premiums, might be worth considering for those with robust emergency funds. However, she cautions, "Never opt for an HDHP if you lack the savings to cover the deductible."&nbsp;
Don't Miss:
<ul>
<li>Many are using this retirement income calculator to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on how on what&#8217;s behind this formula.</a></li>
<li><a href="https://www.benzinga.com/money/100k-cd">$100K Sitting In A CD Account, Should I Move Money Into The Stock Market?</a></li>
</ul>
An HDHP can be paired with a Health Savings Account (HSA), a powerful tool that offers a "triple tax break" – contributions grow tax-free, are tax-deductible and withdrawals for medical expenses are untaxed. Plus, some employers match contributions, adding an extra boost to savings.
Beyond health coverage, Medicaid expansions in 40 states have broadened access for low-income families, but there's ongoing debate about how financially sustainable this will be in the long run.&nbsp;
Policy experts, like those at the Kaiser Family Foundation, highlight the importance of keeping up with changes in Medicaid eligibility and benefits as states adjust policies. These expansions, though beneficial, come with a need for beneficiaries to stay informed on any premium adjustments or updates in coverage tiers.
Trending: Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.
For those with dependents, relying solely on employer-provided life insurance is a mistake, <a href="https://www.benzinga.com/personal-finance/financial-advisors/24/10/41553671/the-wealthy-follow-suze-ormans-golden-rule-for-getting-rich-she-says-theres-1">according to Orman</a>. Employer policies typically cover only one to two years of salary – far from adequate. "My advice," she stresses, "is to aim for a life insurance policy that's 20 to 25 times your current salary."&nbsp;
This recommendation is particularly vital for families with young children or a stay-at-home parent who would otherwise face hefty costs for child care if the caregiver passes away unexpectedly.
Trending: This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.
Orman also points out the importance of emergency savings, noting that many employers now offer programs to help workers build a financial safety net. Some companies even match contributions to these savings plans, providing a solid foundation against life's inevitable surprises.&nbsp;
If one's employer doesn't offer this benefit, Orman suggests asking HR about "split deposit" options, allowing a portion of each paycheck to be automatically directed into a savings account. For those who need more support, she recommends SecureSave, a tool she cofounded to give employees a straightforward way to build emergency savings.
See Also: According to Vanguard&#8217;s Advisor&#8217;s Alpha Study, working with a financial advisor can result in approximately 3% higher net returns annually,<a href="https://www.benzinga.com/money/3-percent-advantage-financial-advisor"> here are the benefits of partnering with a financial advisor and how to find the right one near you in minutes.</a>
Retirement planning is another area Orman urges individuals not to overlook. She recommends saving at least 15% of one's income for retirement, combining personal and employer contributions. Increasing the contribution rate can make a significant difference over time for employees not yet at that target.
Orman's advice comes when economic uncertainty also impacts food security, with organizations like the Food and Agriculture Organization raising concerns about food affordability worldwide. Programs like the Supplemental Nutrition Assistance Program (SNAP) have become essential to many households.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
</ul>

Personal Finance

Suze Orman Warns It's On You To Make Sure You Have The Right Coverage For 2025 And Beyond – 'Don't Rely On Workplace Life Insurance'

JP Morgan analyst Michael Rehaut maintains Beacon Roofing Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BECN#NASDAQ">BECN</a>) with a Overweight and raises the price target from $110 to $119.

BECN

JP Morgan Maintains Overweight on Beacon Roofing Supply, Raises Price Target to $119

RBC Capital analyst Mike Dahl maintains Owens-Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>) with a Outperform and raises the price target from $213 to $217.

RBC Capital Maintains Outperform on Owens-Corning, Raises Price Target to $217

Alyse Amores' trading journey started in 2017 with just $300, a leap of faith and the determination of a single mother wanting more for her family.&nbsp;
In her interview with Trading Nut, Amores detailed how she grew that initial $300 into a seven-figure trading account in just five years – without a background in finance or investing. Her story isn't <a href="https://www.benzinga.com/personal-finance/24/09/40711869/how-rich-are-you-heres-the-net-worth-that-defines-upper-middle-and-lower-class">just about financial success</a>, but also about discipline, strategy and resilience. Here are her most valuable lessons for new traders.
Don't Miss:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>This well known prop trading firm is offering 100% of your first $25,000 profit per account and 90% after that. <a href="https://www.benzinga.com/money/apex-trader-funding">Here's how to get a special 50% OFF CODE that lets you start out with monthly investments as low as $147 today.</a></li>
</ul>
Starting with Small, Realistic Goals
Amores <a href="https://www.benzinga.com/personal-finance/24/06/39439265/single-mom-with-1-3-million-from-divorce-cant-afford-8-000-monthly-rent-dave-ramsey-says-its-tim">didn't jump in with massive goals</a> or big capital. "My first goal was just to earn five or six hundred dollars a week," she explained. "If I could replace my side hustle, that would already be huge for me." She only invested $300 initially, even though she could have put in more. Her approach was simple: if she couldn't grow $300, she wasn't ready to trade larger amounts. "If you can't grow $300, you won't be able to grow $3,000 or $30,000," she noted.
As her skills developed, so did her targets. Within six months, her weekly earnings exceeded her biweekly paycheck and she built a full year's salary in savings – enough to safely leave her job. "I couldn't just leave my job and hope for the best. I had to be prepared and have a safety net for my family," she said. This cautious approach allowed her to build her confidence and skills without feeling pressured to "make it big" overnight.
Trending: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic&nbsp;</a>
Learning from Mentors and the Power of Networking
One critical element in Amores' journey was finding experienced traders to guide her. Rather than trying to teach herself everything, she sought out mentors at every new level. "Try to learn from someone vetted, with proof they are who they say they are," she advised, adding that a solid mentor saved her from wasting time on beginner strategies when she was ready for more advanced skills.
Through networking, Amores went from managing her own account to working with proprietary trading firms and eventually handling larger fund accounts. "Every fund I've traded for came through referrals," she explained. "You never know who you're talking to, so always show up as your best self." These connections shaped her trading journey, each one opening new doors and bigger opportunities.
Trending: With over 7.8K investors including Meta, Google, And Amazon Execs — this AI Startup's valuation has skyrocketed from $5 million to $85 million in just three years. <a href="https://www.benzinga.com/money/rad-ai">Be an early investor with just $1,000 for only $0.50/share today.</a>
Managing Emotions Through Visualization and Focused Preparation
For Amores, successful trading isn't only about strategy. Mental resilience plays a significant role. To manage the stress of large trades, she developed a daily routine that includes visualization techniques.&nbsp;
"I visualize myself trading calmly, even when numbers aren't going my way," she said. She learned to avoid impulsive decisions that could undermine her trades by focusing on staying calm. This emotional control, coupled with a focused morning routine – whether calming music, affirmations or reviewing her goals – allowed her to approach each trading day clearheaded and prepared.
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a>
Looking to the Future – With Big Goals and Bigger Ambitions
Today, Amores <a href="https://www.benzinga.com/personal-finance/24/06/39339348/can-you-guess-how-much-of-the-stock-market-the-richest-10-own-hint-its-more-than-you-think">trades multimillion-dollar accounts</a> and aspires to handle billion-dollar allocations. For her, trading has been about more than just building wealth; it's about challenging herself and achieving new milestones.&nbsp;
Her journey reminds us that success in trading comes from persistence, self-discipline and a commitment to continuous improvement. Amores' story isn't just inspiring – it's a practical guide for anyone looking to make their mark in trading.
Read Next:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

A Single Mom Transformed $300 Into A 7-Figure Trading Empire in Just 5 Years – Here Are Her Best Tips for New Traders

WIIM

MBLY

Mobileye Global shares are trading higher after the company announced the launch of its MIPS P8700 Series RISC-V Processor.

JP Morgan analyst Harlan Sur maintains ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with a Overweight and raises the price target from $140 to $160.

JP Morgan Maintains Overweight on ARM Holdings, Raises Price Target to $160

Myomo shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance above estimates.

IonQ Inc.&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares are barreling higher Thursday after the company reported better-than-expected third-quarter results and announced a series of partnerships. Multiple analysts raised price targets following the print, which appears to be adding to the upward momentum. Here&#8217;s <a href="https://www.benzinga.com/news/earnings/24/11/41789866/ionq-q3-earnings-revenue-beat-eps-miss-bookings-jump-on-air-force-research-contract-guidance-raise-">what you need to know.</a>
What To Know: IonQ reported third-quarter revenue of $12.4 million, beating analyst expectations of $10.56 million. The company posted a loss of 24 cents per share, versus an expected loss of 21 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Total revenue grew 102% year-over-year, and the company saw $63.5 million in new bookings, bolstered by a $54.5 million contract with the U.S. Air Force Research Lab (AFRL) to enhance quantum hardware for scaling and networking applications.
IonQ also raised its full-year 2024 revenue forecast to a range of $38.5 million to $42.5 million, up from a previous range of $38 million to $42 million.
Following the company&#8217;s quarterly results, Benchmark analyst David Williams maintained IonQ with a Buy and raised the price target from $12 to $22. Needham analyst Quinn Bolton also maintained a Buy rating and raised the price target from $13 to $18.
See Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a>
What Else: IonQ announced the creation of a new quantum application development center in collaboration with AstraZeneca. The companies will partner on the development of quantum applications.
IonQ also announced partnerships with Ansys and NKT Photonics. The company will work with Ansys to integrate quantum computing into the computer-aided engineering industry. IonQ said it will work with NKT Photonics to develop next-generation laser systems for its trapped-ion quantum computers and networking equipment.
&#8220;We are pleased to partner with NKT Photonics as they share IonQ&#8217;s vision of developing high-performing, scalable and accessible quantum computers designed for enterprise data center environments,&#8221; said Dave Mehuys, vice president of product engineering at IonQ.
Finally, IonQ announced that it entered into a definitive agreement to acquire California-based quantum networking company Qubitekk. The acquisition is expected to close in the next six months. As part of the transaction, the Qubitekk team will join IonQ to further IonQ&#8217;s position in the quantum networking industry. 
IONQ Price Action: IonQ shares were up 35.7% at $22.33 at the time of publication, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="534" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-1024x534.png" alt="" class="wp-image-635746" style="width:454px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-1024x534.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq-768x401.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/07112406/ionq.png 1162w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41814454/donald-trump-could-pardon-ross-ulbricht-january-6-protestors-and-one-other-controversial-f">Donald Trump Could Pardon Ross Ulbricht, January 6 Protestors And One Other Controversial Figure, Polymarket Traders Speculate</a></li>
</ul>
Image Via Shutterstock.

Movers

IONQ

IonQ Stock Is Soaring Thursday: What's Going On?

JP Morgan analyst Cory Carpenter maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Neutral and raises the price target from $160 to $200.

JP Morgan Maintains Neutral on AppLovin, Raises Price Target to $200

Baird analyst Timothy Wojs maintains Fortune Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBIN#NYSE">FBIN</a>) with a Neutral and lowers the price target from $94 to $90.

FBIN

Baird Maintains Neutral on Fortune Brands, Lowers Price Target to $90

US Foods Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USFD#NYSE">USFD</a>) reported third-quarter adjusted earnings per share of 85 cents,<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41801904/us-foods-reports-third-quarter-fiscal-year-2024-earnings" rel="noreferrer noopener"> beating the street view of 83 cents.</a> Quarterly sales of $9.728 billion (+6.8%) outpaced the analyst consensus estimate of $9.718 billion,&nbsp;driven by total case volume growth and food cost inflation of 3.2%.
&#8220;We delivered strong results in the&nbsp;third quarter&nbsp;despite the softer macro environment and weather-related challenges which pressured industry case volumes,&#8221; said Dave Flitman, CEO.
In its latest quarterly earnings, US Foods reported a 3.8% increase in total case volume, with independent restaurant case volume rising by 4.1%. The company&#8217;s gross profit grew by 8.1%, reaching $1.7 billion.
Net income for the quarter was $148 million, while adjusted EBITDA increased 13.2% to $455 million.
Adjusted gross profit was $1.7 billion, an increase of 7.0% from the prior year. Adjusted gross profit as a percentage of net sales was 17.4%.
Also Read:<a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41812800/papa-johns-earns-less-dough-as-q3-sales-dip-ceo-blames-challenging-consumer-environment" rel="noreferrer noopener"> Papa John&#8217;s Earns Less Dough As Q3 Sales Dip, CEO Blames &#8216;Challenging Consumer Environment&#8217;</a>
Net debt at the end of the third quarter of fiscal year 2024 was $4.7 billion. The company exited the quarter with cash and equivalents worth $81 million. Long-term debt as of quarter-end totaled $4.671 billion.
At the end of the third quarter, the company had approximately $398 million in remaining funds authorized under its $1 billion share repurchase program.
&#8220;In the face of the softer macro backdrop, we continue to grow sales, expand margins and deploy our strong free cash flow,&#8221; said Dirk Locascio, CFO. &#8220;Additionally, we allocated $580 million of capital during the quarter toward share repurchases while maintaining a strong balance sheet.&#8221;
Outlook: US Foods Holding tightened its FY24 net sales outlook to $37.7 billion &#8211; $38.0 billion, compared to the prior view of $37.5 billion &#8211; $38.5 billion and the <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">analyst estimate of $37.84 billion.</a>
The company also projects adjusted diluted earnings per share of $3.05 &#8211; $3.15, narrower than the prior view of $3.00 &#8211; $3.20, compared with the $3.08 estimate.
Price Action: USFD shares are trading higher by 0.36% to $66.04&nbsp;at last check Thursday.
Also Read:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41806970/hersheys-q3-earnings-sour-as-sales-dip-and-outlook-darkens-ceo-pledges-aggressive-turnaround-amid-h" target="_blank" rel="noreferrer noopener">Hershey&#8217;s Q3 Earnings Sour As Sales Dip And Outlook Darkens; CEO Pledges Aggressive Turnaround Amid High Cocoa Costs</a></li>
</ul>

Equities

Guidance

General

USFD

US Foods Beats Q3 Expectations As Sales And Case Volumes Surge, Tightens FY24 Outlook

Baird analyst David Tarantino maintains Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) with a Neutral and raises the price target from $37 to $46.

BROS

Baird Maintains Neutral on Dutch Bros, Raises Price Target to $46

<a href="https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies" title="https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies">https://www.gevernova.com/news/press-releases/ge-vernova-expands-strategic-collaboration-agreement-aws-help-energy-companies</a>

AMZN

GE Vernova Expands Collaboration With AWS To Accelerate Energy Transition, Integrating Asset Performance Management And CERius Software On AWS Cloud

Nexstar Media Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXST#NASDAQ">NXST</a>) shares are trading higher. The company reported a third-quarter fiscal year 2024 net revenue increase of 20.7% year over year to $1.366 billion. That&#8217;s <a href="https://www.benzinga.com/pressreleases/24/11/b41802369/nexstar-media-group-reports-record-third-quarter-net-revenue-of-1-37-billion" target="_blank" rel="noreferrer noopener">in line with the consensus</a>.
<ul>
<li>Revenues from Advertising rose&nbsp;22.2% to&nbsp;$622 million. The growth was led by a $135 million year-over-year rise in election-year political advertising.</li>
<li>Distribution revenue gained&nbsp;20.2% to&nbsp;$719&nbsp;million. This growth was driven by the resolution of a 2023 MVPD dispute, favorable contract renewals, annual rate increases, higher vMVPD subscribers, new CW affiliations, and the return of partner stations.</li>
<li>Adjusted EBITDA jumped&nbsp;82.8% Y/Y to&nbsp;$510 million, and the margin expanded to&nbsp;37.3% from&nbsp;24.6% a year ago.</li>
<li>EPS was&nbsp;$5.27, up from&nbsp;$0.70 in the prior year quarter but&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">below the consensus of&nbsp;$5.40.</a></li>
<li>Adjusted free cash flow totaled&nbsp;$327 million, up from&nbsp;$81 million in the prior year quarter. As of September 30, 2024, unrestricted cash stood at&nbsp;$181 million.</li>
</ul>
Buyback: The company repurchased shares worth $178&nbsp;million in the quarter. The company announced a new $1.5 billion share repurchase authorization in July 2024.
Nexstar CEO Perry A. Sook said, &#8221;During the quarter, we made further progress on our strategy for The CW, reducing operating losses by $36 million year-over-year and by $119 million year-to-date.&#8221;
&#8221;We debuted NASCAR Xfinity Series racing in September and WWE NXT wrestling in October on The CW broadcast network to double-digit percentage increases both in total audience and in adults 18-49 versus previous viewership on cable.&#8221;
Investors can gain exposure to the stock via&nbsp;LeaderShares AlphaFactor Tactical Focused ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSAT#NYSE">LSAT</a>) and Northern Lights Fund Trust IV Monarch Dividend Plus Index ETF (MDPL).
Price Action: Nexstar shares are up 2.92% at $188.60 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41815459" target="_blank" rel="noreferrer noopener">Rockwell Automation&#8217;s Mixed&nbsp;Q4: EPS&nbsp;Beats&nbsp;Amid 21%&nbsp;Sales Drop And Cautious FY25&nbsp;Outlook</a></li>
</ul>
Image:

Mid Cap

LSAT

NXST

Nexstar Media Q3: Political Ads, Distribution Gains Drive 21% Revenue Growth

Donald Trump's 2024 presidential win could prompt his hush money trial sentencing to be dismissed before the <a href="https://www.benzinga.com/general/politics/24/09/40754802/trump-hush-money-sentencing-will-now-take-place-after-2024-election-to-avoid-any-appearance-to-a">scheduled Nov. 26 date.</a>
What Happened: Trump <a href="https://www.benzinga.com/general/politics/24/05/39100065/trump-found-guilty-on-all-34-counts-in-hush-money-criminal-trial-heres-what-happens-next">was found guilty </a>on 34 counts of falsified business records in May in a New York trial known as the hush money trial.
Key witness testimony from former lawyer Michael Cohen and adult actress Stormy Daniels led to the 12-person jury finding Trump guilty on all 34 counts.
Sentencing was originally planned for July, but <a href="https://www.benzinga.com/general/politics/24/07/39609026/donald-trump-hush-money-trial-sentencing-delayed-to-september-18-the-supreme-court-immunity-impa">was delayed </a>by Judge Juan Merchan to Sept. 18 due to a Supreme Court ruling that granted partial immunity to Trump.
Judge Merchan postponed the sentencing from September to Nov. 26 to distance the trial from the 2024 election.
With Trump winning, legal experts now believe Merchan will call off the sentencing.
"I think any reasonable judge wouldn't sentence the president-elect," retired New York trial judge Jill Konviser said, as <a href="https://www.politico.com/news/2024/11/06/trump-sentencing-probably-wont-happen-00187999">reported </a>by Politico.
Set to be inaugurated as president in January, legal experts say Trump could argue that any sentencing, whether it be jail, home confinement or community service would interfere with his upcoming presidential duties.
Former Manhattan assistant district attorney Jeremy Saland doesn't see the sentencing moving ahead.
"The former president/president-elect does not get sentenced," Saland told Politico.
Former prosecutor Neama Rahmani said Merchan may not "have the stomach to imprison a former president or president-elect,&#8221; as <a href="https://nypost.com/2024/11/07/us-news/judge-in-trumps-hush-money-trial-considers-tossing-felony-conviction/">reported </a>by the New York Post. 
"Now that Trump has won, his criminal problems go away," Rahmani said.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
What's Next: Judge Merchan will be tasked with sentencing in the case if nothing changes. Each of the 34 counts of which Trump was found guilty comes with a punishment of up to four years in prison. Trump is unlikely to receive prison time due to having no criminal record.
The sentence is also <a href="https://www.usatoday.com/story/news/factcheck/2024/05/31/trump-prison-time-fact-check/73916922007/">limited </a>to the total number of years Trump could face in prison, with New York limiting consecutive sentences for Class E felonies to a maximum of 20 years.
While he may not face prison time, a sentence of probation or home confinement could still occur and come ahead of inauguration day.
One option for Merchan would be to continue with the planned sentencing on Nov. 26 and any ruling would be deferred until 2029 when Trump is out of the White House. Merchan could also delay the sentencing until Trump is out of office.
The hush money trial is not the only case against Trump, with three other criminal cases currently pending. Each of these cases could also be closed after Trump's 2024 election victory.
Merchan also has to rule on a request by Trump for the guilty verdict to be thrown out after the Supreme Court ruling on presidential immunity. That ruling is currently scheduled for Nov. 12 and could make the Nov. 26 sentencing a non-issue.
While any prison sentence would complicate Trump&#8217;s presidency, there are <a href="https://www.benzinga.com/news/23/07/33446444/donald-trump-will-still-run-for-president-if-convicted-and-right-now-thats-perfectly-legal" target="_blank" rel="noopener">no current rule</a><a href="https://www.benzinga.com/news/23/07/33446444/donald-trump-will-still-run-for-president-if-convicted-and-right-now-thats-perfectly-legal">s</a> against running for president or even being president if incarcerated.
Trump <a href="https://www.benzinga.com/m-a/23/08/33878846/trump-to-maintain-control-of-media-company-if-he-sells-majority-goes-to-jail-or-becomes-president">will also maintain control </a>of his company Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) if he is sentenced to prison.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/41784933/donald-trumps-wealth-soars-with-2024-election-win-heres-how-much-president-elect-is-worth-ho">Donald Trump&#8217;s Wealth Soars With 2024 Election Win: Here&#8217;s How Much President-Elect Is Worth, How Much He&#8217;ll Make In White House</a></li>
</ul>
Photo: Shutterstock

Politics

Legal

Will Trump Be Sentenced In Hush Money Trial Or Will His 'Criminal Problems Go Away'?

Imunon GAAP EPS of -$0.51 beats by $0.04

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Imunon (NASDAQ:<a href="https://investorplace.com/stock-quotes/imnn-stock-quote/">IMNN</a>) just reported results for the second quarter of 2024.<ul><li>Imunon reported earnings per share of -51 cents. This was above the analyst estimate for EPS of -60 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/imnn-stock-earnings-imunon-for-q2-of-2024/">IMNN Stock Earnings: Imunon Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IMNN Stock Earnings: Imunon Beats EPS for Q2 2024

Imunon, Inc. (IMNN) Q2 2024 Earnings Call Transcript

Imunon files to sell up to 5M shares

The latest announcement is out from Imunon ( ($IMNN) ). Imunon, Inc. has appointed Susan Eylward as its new General Counsel and Corporate Secretary...

Imunon Welcomes Susan Eylward as General Counsel, Strengthens Leadership Team

IMUNON (IMNN) announced the acceptance of a late-breaking presentation featuring new clinical data from the Phase 2 OVATION 2 Study of IMNN-001, it...

Imunon to present Phase 2 data of IMNN-001

Imunon Q3 2024 Earnings Preview

Imunon GAAP EPS of -$0.34 beats by $0.06

"The third quarter was a period of important milestones and outstanding progress for IMUNON (IMNN), driven largely by presentation of highly compel...

Imunon reports Q3 EPS (34c), consensus (40c)

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its investigational ...

Imunon presents data from Phase 2 OVATION 2 clinical trial

IMNN

Press Releases

IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024

IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update

IMUNON to Host R&D Day on September 18th

IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management

Comments

Imunon

Notizie

Ultime notizie per Imunon (NASDAQ:IMNN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO